New York State Teachers Retirement System lowered its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating) by 2.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 123,270 shares of the biopharmaceutical company’s stock after selling 3,382 shares during the period. New York State Teachers Retirement System owned about 0.11% of Regeneron Pharmaceuticals worth $88,938,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds have also recently made changes to their positions in REGN. Massachusetts Financial Services Co. MA acquired a new stake in Regeneron Pharmaceuticals in the third quarter valued at $136,678,000. Great West Life Assurance Co. Can acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter valued at approximately $116,414,000. Ardevora Asset Management LLP bought a new position in Regeneron Pharmaceuticals during the 4th quarter worth approximately $66,473,000. Pictet Asset Management SA increased its position in shares of Regeneron Pharmaceuticals by 32.2% during the third quarter. Pictet Asset Management SA now owns 346,514 shares of the biopharmaceutical company’s stock worth $238,703,000 after buying an additional 84,405 shares during the period. Finally, Vanguard Group Inc. raised its stake in Regeneron Pharmaceuticals by 0.9% during the third quarter. Vanguard Group Inc. now owns 8,648,125 shares of the biopharmaceutical company’s stock worth $5,957,433,000 after buying an additional 77,380 shares during the last quarter. Institutional investors own 84.25% of the company’s stock.
Regeneron Pharmaceuticals Price Performance
NASDAQ REGN opened at $828.73 on Monday. The company has a market cap of $90.61 billion, a PE ratio of 21.67, a price-to-earnings-growth ratio of 2.43 and a beta of 0.23. The company has a quick ratio of 4.29, a current ratio of 5.06 and a debt-to-equity ratio of 0.12. The firm’s 50-day simple moving average is $772.66 and its two-hundred day simple moving average is $745.67. Regeneron Pharmaceuticals, Inc. has a 52 week low of $538.01 and a 52 week high of $837.55.
Analysts Set New Price Targets
A number of analysts have weighed in on the company. Morgan Stanley increased their price target on Regeneron Pharmaceuticals from $868.00 to $873.00 and gave the stock an “overweight” rating in a report on Tuesday, January 24th. StockNews.com started coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, March 16th. They issued a “buy” rating for the company. Barclays raised their price target on shares of Regeneron Pharmaceuticals from $815.00 to $915.00 and gave the stock an “overweight” rating in a report on Friday, March 24th. SVB Leerink raised shares of Regeneron Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Monday, March 27th. Finally, Robert W. Baird upped their target price on Regeneron Pharmaceuticals from $756.00 to $800.00 and gave the stock a “neutral” rating in a research report on Friday, March 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nineteen have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $840.57.
Insider Buying and Selling at Regeneron Pharmaceuticals
In other Regeneron Pharmaceuticals news, CFO Robert E. Landry sold 183 shares of the firm’s stock in a transaction on Monday, March 27th. The shares were sold at an average price of $821.70, for a total value of $150,371.10. Following the completion of the transaction, the chief financial officer now directly owns 32,929 shares of the company’s stock, valued at approximately $27,057,759.30. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, SVP Christopher R. Fenimore sold 2,192 shares of the stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $806.47, for a total value of $1,767,782.24. Following the transaction, the senior vice president now owns 18,409 shares of the company’s stock, valued at approximately $14,846,306.23. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Robert E. Landry sold 183 shares of the company’s stock in a transaction on Monday, March 27th. The stock was sold at an average price of $821.70, for a total transaction of $150,371.10. Following the completion of the transaction, the chief financial officer now owns 32,929 shares of the company’s stock, valued at $27,057,759.30. The disclosure for this sale can be found here. Insiders sold 29,986 shares of company stock valued at $23,933,592 in the last quarter. 8.99% of the stock is currently owned by corporate insiders.
Regeneron Pharmaceuticals Profile
Regeneron Pharmaceuticals, Inc is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies.
Featured Stories
- Get a free copy of the StockNews.com research report on Regeneron Pharmaceuticals (REGN)
- Alibaba’s Turn At Bat For ChatGPT Competition, How to Manage Risk
- 2 Under-The-Radar Small Chip Stocks Poised For Big Growth
- Novartis Shares Leap On Positive Clinical Trial Data
- MarketBeat Week in Review – 4/3 – 4/7
- Costco Sales Disappoint, Markets Are Missing This Upside Driver
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Rating).
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
